These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12358269)

  • 1. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
    Kumar KS; Russo MW; Borczuk AC; Brown M; Esposito SP; Lobritto SJ; Jacobson IM; Brown RS
    Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
    Midturi J; Sierra-Hoffman M; Hurley D; Winn R; Beissner R; Carpenter J
    Clin Infect Dis; 2004 Dec; 39(11):1724-9. PubMed ID: 15578378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK; Kaplan AL
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
    Bonny C; Fontaine H; Poynard T; Hézode C; Larrey D; Marcellin P; Bourlière M; Bronowicki JP; Merle P; Zarski JP; Sapey T; Guillemard C; Ughetto S; Henquell C; Nicolas C; Roche C; Randl K; Bommelaer G; Abergel A
    Aliment Pharmacol Ther; 2006 Aug; 24(4):593-600. PubMed ID: 16907892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
    Sharvadze L; Gochitashvili N; Tophuria A; Bolokadze N; Tsertsvadze T
    Georgian Med News; 2007 Jun; (147):52-5. PubMed ID: 17660602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
    Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
    J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction models for feverishness developed during interferon therapy of chronic hepatitis C patients.
    Uesawa Y; Motege E; Dai Y; Ishii K; Mohri K
    Pharmazie; 2010 Feb; 65(2):114-6. PubMed ID: 20225655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
    TreatmentUpdate; 2001; 12(8):4-5. PubMed ID: 12132439
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment.
    Toccaceli F; Rosati S; Scuderi M; Iacomi F; Picconi R; Laghi V
    Hepatogastroenterology; 1998; 45(23):1748-52. PubMed ID: 9840140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child?
    Serranti D; Buonsenso D; Ceccarelli M; Gargiullo L; Ranno O; Valentini P
    Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1057-67. PubMed ID: 22013729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-induced psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion.
    Silverman BC; Kim AY; Freudenreich O
    Psychosomatics; 2010; 51(1):1-7. PubMed ID: 20118434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir.
    Bernardeschi C; Valeyrie-Allanore L; Ortonne N; Gressier L; Wallet-Faber N; Bernard PH; Hezode C; Duclos-Vallée JC; Samuel D; Mallet V; Pol S; Milpied B; Dupin N
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):143-6. PubMed ID: 25187266
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
    Gao X; Stephens JM; Carter JA; Haider S; Rustgi VK
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):335-43. PubMed ID: 22812557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C: ribavirin and/or interferon?
    Heathcote J
    Rev Gastroenterol Mex; 1996; 61(4 Suppl 2):S71-5. PubMed ID: 8986103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.